Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATEAU: Triple Checkpoint Blockade in Post-CAR T DLBCL
NCT06290622Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of retifanlimab, tuparstobart and verzistobart in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma (HGBCL) and 1 more, sponsored by University of Alabama at Birmingham. Primary endpoint: Optimal Biological Dose at 24 months. Planned start Aug 2024; status: withdrawn.
02
Drugs
retifanlimabtuparstobartverzistobart
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06290622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290622.